Nasal Fentanyl for Patient Controlled Treatment of Pain in Cancer (NFCP1-2010)
Nasal Fentanyl for Patient Controlled Treatment of Pain in Cancer An Open Label Prospective Phase I b Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Trondheim, Norway, 7006
- St.Olavs university hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Cancer patients with metastatic disease
- Adult (older than 18 years)
- Life expectancy of > 3 months
- Cancer-related pain > 3 on an 11 point Numerical Rating Scale (NRS)
- In the need of opioids (step II or III)
- Able to use nasal drugs.
- Women of child bearing potential using adequate contraception
- Informed consent given according to applicable requirements before any trial-related activities. Trial-related activities are any procedure that would not have been performed during the routine management of the patient
Exclusion Criteria:
- History of substance abuse
- Cognitive impairment which makes the patient unable to complete questionnaires or not able to comply with the study procedures
- Treated with MAO inhibitor within the last 14 days
- Known hypersensitivity to study drug or specific contraindications to the study drug
- Nasopharyngeal device such as gastric tube
- Concomitant participation in any other trials dealing with pain with an investigational drug or device apart from cancer treatment within 14 days prior to inclusion in this trial
- Pathological conditions of the nasal cavity as contraindication to nasal fentanyl
- Sleep apnoea syndrome
- Pregnant or breastfeeding women
- Psychiatric disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: fentanyl
cancer patients with pain
|
nasally, dose titrated to effect
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
sedation/drowsiness
Time Frame: 10 days
|
scores on a 0-10 numerical rating scale; 0=none / 10=intolerable
|
10 days
|
|
nausea and vomiting
Time Frame: 10 days
|
nausea scores on a 0-10 numerical rating scale; 0=none / 10=intolerable vomiting yes/no
|
10 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
pain intensity
Time Frame: 10 days
|
scores on a 0-10 numerical rating scale; 0=none / 10=intolerable
|
10 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Stein Kaasa, MD. PhD, St.Olav's Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NFCP1-2010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.